19 February 2025
: Case report 
Extragastrointestinal Stromal Tumor Mimicking Appendicitis: A Case Study
Unusual clinical course, Challenging differential diagnosis, Rare coexistence of disease or pathology
Ricardo Martinez ABDEFG 1, Michael Lezcano ABDEFG 1, Jonak Randhawa ABDEFG 1, Shahryar Aijaz ABDEFG 1, Yara Al Mazouni ABDEFG 1, Ahmed Altamimi ABDEFG 2,3*, Norka Camacho-Perez ABDEFG 1, Feras Othman ABDEFG 4, Andrew M. O'Neill ACD 3, Joshua A. Simon BCD 3DOI: 10.12659/AJCR.944665
Am J Case Rep 2025; 26:e944665
Table 2. Follow-up of gastrointestinal stromal tumor (GIST) patients treated with surgery and adjuvant imatinib [19].
| Risk group | During adjuvant imatinib (currently administered for 3 years) | The 2 years that follow discontinuation of adjuvant imatinib | The rest of the follow-up period (up to approximately 10 years from imatinib initiation) |
| High risk (30% to 100% risk) | Abdominal/pelvic computerized tomography (CT)/magnetic resonance imaging (MRI) every 6 months | Abdominal/pelvic CT/MRI at 3 to 4 month intervals | Abdominal/pelvic CT at 6 to 12 month intervals |
| * Patients who discontinue adjuvant imatinib early due to intolerance are followed up as other patients who discontinue adjuvant imatinib. ** Patients with a high tumor mitotic count may require more frequent imaging while being treated with adjuvant imatinib. | |||